Several other research analysts have also recently commented on the stock. Citigroup increased their target price on shares of Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the stock a buy rating in a report on Monday, August 20th. Barclays restated an underweight rating on shares of Hikma Pharmaceuticals in a report on Monday, September 17th. JPMorgan Chase & Co. restated a neutral rating and set a GBX 1,050 ($13.72) target price on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Finally, Numis Securities restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of GBX 1,346.89 ($17.60).
Shares of HIK opened at GBX 1,752.50 ($22.90) on Tuesday. Hikma Pharmaceuticals has a 12 month low of GBX 814.20 ($10.64) and a 12 month high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
See Also: What are earnings reports?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.